SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today announced that the Company’s MicroThermX® Microwave Ablation System (MicroThermX) products were showcased at the annual medical conference of the Society of Interventional Radiology (SIR). SIR was held March 22 to 27, 2014, in San Diego. The SIR conference is the world’s most comprehensive interventional radiology meeting. The conference theme was "Convergence," which was chosen to emphasize that "…image-guided therapies are fast proving the best option for patients with a wide variety of pathologic entities." Over 5,000 physicians, scientists and health professionals from around the world attended the meeting. The potential global market for ablation treatments is expected to reach $2.0 billion.
BSD featured the MicroThermX at the Company’s exhibition booth and focused on the advantages of the innovative, synchronous wave alignment technology included in MicroThermX. BSD also participated in two SIR workshops on ablation technology. Both workshops allowed BSD to provide hands-on training and demonstrate the advantages of synchronous wave alignment technology for treating large tumors.
"We significantly increased the profile of the Company’s microwave ablation products and strengthened the Company’s relationships with key opinion leaders throughout the world," said Brian Ferrand, BSD's V.P. of Domestic Sales. "Due to our targeted marketing programs at SIR, we more than doubled the number of sales leads we obtained at the conference, as compared to last year. We are making excellent progress towards increasing our brand's presence in the interventional oncology marketplace."
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the US FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
